{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.3","upperLimit":"24.6","value":"16.1"}]}],"title":"Acute GVHD (grade II-IV)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"9.0","value":"3.4"}]}],"title":"Chronic GVHD"}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"}],"units":"Participants"}],"description":"Acute GVHD is defined by the Przepiorka criteria, which stages the degree of organ involvement in the skin, liver, and gastrointestinal (GI) tract, based on severity, with Stage 1+ being least severe and stage 4+ being the most severe. Grading of acute GVHD is as follows: Grade II (skin involvement stages 1+ to 3+, liver 1+, GI tract 1+), Grade III (skin involvement stages 2+ to 3+, liver 1+, GI tract 2+ to 4+), Grade IV (skin involvement stages 4+, Liver 4+).\n\nChronic GVHD is assessed by NIH consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11:945-56., for grading criteria. (See Citation: Filipovich AH et al)\n\nThe incidence of patients with acute GVHD (Grade II-IV) was determined at 180 days. The incidence of Chronic GVHD by 2 years was reported","dispersionType":"95% Confidence Interval","groups":[{"description":"Although the protocol initially had different disease intensities, ultimately, moved to one regimen for all patients. Subjects received 30mg/m\\^2 of Fludarabine from Day-7 until Day-3, 140mg/m\\^2 of Melphalan on Day-2, and 1.5mg/kg of Rabbit antithymocyte globulin at Day-7,-5,-3 and -1.\"","id":"OG000","title":"Treatment Group"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Percentage of Participants With Incidence of Acute (Grade II-IV) and Chronic Graft-vs-host Disease(GVHD)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}